2025 Q4 -tulosraportti
21 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 209 | - | - | ||
| 314 | - | - | ||
| 77 | - | - | ||
| 223 | - | - |
Ylin
20,8VWAP
Alin
20,5VaihtoMäärä
0 829
VWAP
Ylin
20,8Alin
20,5VaihtoMäärä
0 829
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·22 t sittenAnonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
·2 päivää sittenNorne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.·2 päivää sittenWhat is the source, Fevang?·23 t sittenNorne (Slyngstadli) nevertheless has a positive view on Navamedic long-term, and a price target of 28 (for what these analyses and price targets are worth. That can certainly be discussed ;-) I mentioned on the thread here recently that it may take 2-3 years before the investment here can be said to be good, or not. Time will tell.
·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.- ·26.2.For those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "
- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
21 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenAnonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
- ·2 päivää sittenNorne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.·2 päivää sittenWhat is the source, Fevang?·23 t sittenNorne (Slyngstadli) nevertheless has a positive view on Navamedic long-term, and a price target of 28 (for what these analyses and price targets are worth. That can certainly be discussed ;-) I mentioned on the thread here recently that it may take 2-3 years before the investment here can be said to be good, or not. Time will tell.
- ·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
- ·26.2.For those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "
- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 209 | - | - | ||
| 314 | - | - | ||
| 77 | - | - | ||
| 223 | - | - |
Ylin
20,8VWAP
Alin
20,5VaihtoMäärä
0 829
VWAP
Ylin
20,8Alin
20,5VaihtoMäärä
0 829
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
21 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22 t sittenAnonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
- ·2 päivää sittenNorne Sec: We are making one change in March as we fold our hand in Navamedic. It is taking too long for the company, while the numbers are too poor.·2 päivää sittenWhat is the source, Fevang?·23 t sittenNorne (Slyngstadli) nevertheless has a positive view on Navamedic long-term, and a price target of 28 (for what these analyses and price targets are worth. That can certainly be discussed ;-) I mentioned on the thread here recently that it may take 2-3 years before the investment here can be said to be good, or not. Time will tell.
- ·27.2.Something is happening here... 125 mill turnover·27.2.According to AI, Kistefoss has block-sold its stake to institutional investors., and the rest a bit scattered, hence insider trading.
- ·26.2.For those who are interested in such things: Revised Norne analysis published yesterday: lowers price target to 28. "Navamedic’s 4Q highlighted several encouraging developments. Gross margin improved on a shift toward a more favourable product mix, and growth in core business areas continued to support solid underlying performance. While earnings remained under pressure in 4Q, we see signs that the company’s strategic initiatives are beginning to translate into tangible financial progress, albeit with a gradual turnaround. We therefore reiterate our BUY recommendation, but lower our TP to NOK 28/sh., reflecting updated 4Q inputs and a more conservative near-term outlook. "
- ·20.2.Financials reflect early strategic gains, but the process remains gradual. Although Navamedic delivered solid, tangible gains from its initiatives in 2025, the full payoff is still coming through slowly. In our view, higher costs and elevated amortisation continue to outweigh the positive developments in the near term. Long term, however, the company appears to have a solid strategic roadmap, supporting the potential for a turnaround. From Norne's summary after Q4. Turnaround is the word.·20.2.It's only half a year since I looked a bit into this to see what they are doing, so I'm not up-to-date with the past and Norne's analyses in Nava previously. By the way, I never put much weight on what anal ysts think. I do agree with an yst that it could actually be what we in "old" days called a turnaround candidate. I skimmed through quite a few older reports last weekend actually, and see that there are old fun/misjudgments lingering that cause some challenges, without going into more detail about this. I have a reasonably large position now both here and with Norne, and I am aware that it (as usual) can go both ways. Will follow the development this year. High risk-high reward it is said, I think medium risk-high reward fits better here. Have a good weekend, Bastus :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 209 | - | - | ||
| 314 | - | - | ||
| 77 | - | - | ||
| 223 | - | - |
Ylin
20,8VWAP
Alin
20,5VaihtoMäärä
0 829
VWAP
Ylin
20,8Alin
20,5VaihtoMäärä
0 829
Välittäjätilasto
Dataa ei löytynyt